Technical Analysis for HMDCF - Hutchison China Ltd

Grade Last Price % Change Price Change
C 3.1500 -6.75% -0.2280
HMDCF closed down 6.75 percent on Wednesday, September 20, 2023, on 8.31 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up

Date Alert Name Type % Chg
MACD Bullish Centerline Cross Bullish 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -6.75%
Wide Bands Range Expansion -6.75%
Crossed Above 20 DMA Bullish -5.69%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Hutchison China Ltd Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Clinical Medicine Chemical Compounds Solid Tumors Breast Cancer Colorectal Cancer Immunotherapies Lung Cancer Non Small Cell Lung Cancer Small Cell Lung Cancer Hematological Malignancies Hepatocellular Carcinoma Gastric Cancer Hematological Cancers Ros1 Sarcoma Targeted Therapy Tyrosine Kinase Bemcentinib Esophageal Cancer Follicular Lymphoma Neuroendocrine Tumors Non Small Cell Lung Carcinoma Nsclc Protein Kinase Inhibitor Renal Cell Carcinoma Thyroid Cancer

Is HMDCF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.72
52 Week Low 1.61
Average Volume 602
200-Day Moving Average 0.0000
50-Day Moving Average 3.0346
20-Day Moving Average 2.7819
10-Day Moving Average 2.8972
Average True Range 0.5419
RSI (14) 51.69
ADX 26.42
+DI 51.6075
-DI 36.0726
Chandelier Exit (Long, 3 ATRs) 2.3243
Chandelier Exit (Short, 3 ATRs) 3.6767
Upper Bollinger Bands 3.7156
Lower Bollinger Band 1.8482
Percent B (%b) 0.7
BandWidth 67.1268
MACD Line 0.0126
MACD Signal Line -0.0611
MACD Histogram 0.0736
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.1500
Resistance 3 (R3) 3.1500 3.1500 3.1500
Resistance 2 (R2) 3.1500 3.1500 3.1500 3.1500
Resistance 1 (R1) 3.1500 3.1500 3.1500 3.1500 3.1500
Pivot Point 3.1500 3.1500 3.1500 3.1500 3.1500
Support 1 (S1) 3.1500 3.1500 3.1500 3.1500 3.1500
Support 2 (S2) 3.1500 3.1500 3.1500 3.1500
Support 3 (S3) 3.1500 3.1500 3.1500
Support 4 (S4) 3.1500